Pine Bark Supplementation Blood Pressure Randomized Trial Evidence Table

Structured evidence table for Pine Bark Supplementation Blood Pressure Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.

topicclaimevidence levelcitationsource
Pine Bark Supplementation Blood Pressure Randomized TrialBackground Supplementation with pine bark extract (PBE) may improve risk factors associated with cardiometabolic syndrome (CMS).1Mohammadi S (2025)Does supplementation with pine bark extract improve cardiometabolic risk factors? A systematic review and meta-analysis.
Pine Bark Supplementation Blood Pressure Randomized TrialThe effects of PBE supplementation on cardiometabolic risk factors were evaluated in this systematic review and meta-analysis of randomized controlled trials (RCTs).1Mohammadi S (2025)Does supplementation with pine bark extract improve cardiometabolic risk factors? A systematic review and meta-analysis.
Pine Bark Supplementation Blood Pressure Randomized TrialAs population aging accelerates, identifying modifiable risk factors and preventive strategies for cognitive decline has become increasingly important.2Hsiao Tse-Chia (2026)Combined Fish Oil and Pine Bark Extract Supplementation Improves Short-Term Memory and the Antioxidant Status in Middle-Aged and Older Adults with Mild Cognitive Impairment: A Randomized Double-Blind, Parallel-Group Pilot Study
Pine Bark Supplementation Blood Pressure Randomized Trial4 5 5 6 7 8 9 10 11 10 Mild cognitive impairment (MCI) represents an intermediate stage between normal cognitive function and dementia [], and individuals with MCI have a significantly higher risk of progressing to dementia than cognitively normal individuals [].2Hsiao Tse-Chia (2026)Combined Fish Oil and Pine Bark Extract Supplementation Improves Short-Term Memory and the Antioxidant Status in Middle-Aged and Older Adults with Mild Cognitive Impairment: A Randomized Double-Blind, Parallel-Group Pilot Study
Pine Bark Supplementation Blood Pressure Randomized TrialLifestyle-related factors, including suboptimal dietary patterns, smoking, alcohol use, obesity, and physical inactivity, have been identified as modifiable risk factors for cognitive decline [].2Hsiao Tse-Chia (2026)Combined Fish Oil and Pine Bark Extract Supplementation Improves Short-Term Memory and the Antioxidant Status in Middle-Aged and Older Adults with Mild Cognitive Impairment: A Randomized Double-Blind, Parallel-Group Pilot Study
Pine Bark Supplementation Blood Pressure Randomized Trial1 2 3 Dementia is a major global health concern and a leading cause of disability and dependency among older adults worldwide [].2Hsiao Tse-Chia (2026)Combined Fish Oil and Pine Bark Extract Supplementation Improves Short-Term Memory and the Antioxidant Status in Middle-Aged and Older Adults with Mild Cognitive Impairment: A Randomized Double-Blind, Parallel-Group Pilot Study
topicPine Bark Supplementation Blood Pressure Randomized Trial
claimBackground Supplementation with pine bark extract (PBE) may improve risk factors associated with cardiometabolic syndrome (CMS).
evidence level1
citationMohammadi S (2025)
sourceDoes supplementation with pine bark extract improve cardiometabolic risk factors? A systematic review and meta-analysis.
topicPine Bark Supplementation Blood Pressure Randomized Trial
claimThe effects of PBE supplementation on cardiometabolic risk factors were evaluated in this systematic review and meta-analysis of randomized controlled trials (RCTs).
evidence level1
citationMohammadi S (2025)
sourceDoes supplementation with pine bark extract improve cardiometabolic risk factors? A systematic review and meta-analysis.
topicPine Bark Supplementation Blood Pressure Randomized Trial
claimAs population aging accelerates, identifying modifiable risk factors and preventive strategies for cognitive decline has become increasingly important.
evidence level2
citationHsiao Tse-Chia (2026)
sourceCombined Fish Oil and Pine Bark Extract Supplementation Improves Short-Term Memory and the Antioxidant Status in Middle-Aged and Older Adults with Mild Cognitive Impairment: A Randomized Double-Blind, Parallel-Group Pilot Study
topicPine Bark Supplementation Blood Pressure Randomized Trial
claim4 5 5 6 7 8 9 10 11 10 Mild cognitive impairment (MCI) represents an intermediate stage between normal cognitive function and dementia [], and individuals with MCI have a significantly higher risk of progressing to dementia than cognitively normal individuals [].
evidence level2
citationHsiao Tse-Chia (2026)
sourceCombined Fish Oil and Pine Bark Extract Supplementation Improves Short-Term Memory and the Antioxidant Status in Middle-Aged and Older Adults with Mild Cognitive Impairment: A Randomized Double-Blind, Parallel-Group Pilot Study
topicPine Bark Supplementation Blood Pressure Randomized Trial
claimLifestyle-related factors, including suboptimal dietary patterns, smoking, alcohol use, obesity, and physical inactivity, have been identified as modifiable risk factors for cognitive decline [].
evidence level2
citationHsiao Tse-Chia (2026)
sourceCombined Fish Oil and Pine Bark Extract Supplementation Improves Short-Term Memory and the Antioxidant Status in Middle-Aged and Older Adults with Mild Cognitive Impairment: A Randomized Double-Blind, Parallel-Group Pilot Study
topicPine Bark Supplementation Blood Pressure Randomized Trial
claim1 2 3 Dementia is a major global health concern and a leading cause of disability and dependency among older adults worldwide [].
evidence level2
citationHsiao Tse-Chia (2026)
sourceCombined Fish Oil and Pine Bark Extract Supplementation Improves Short-Term Memory and the Antioxidant Status in Middle-Aged and Older Adults with Mild Cognitive Impairment: A Randomized Double-Blind, Parallel-Group Pilot Study

Source documents

  1. Does supplementation with pine bark extract improve cardiometabolic risk factors? A systematic review and meta-analysis.
  2. Combined Fish Oil and Pine Bark Extract Supplementation Improves Short-Term Memory and the Antioxidant Status in Middle-Aged and Older Adults with Mild Cognitive Impairment: A Randomized Double-Blind, Parallel-Group Pilot Study